This study evaluated serum galectin-3 and sICAM-1 levels in patients with type 2 diabetes mellitus (T2DM) who were hospitalized with COVID-19 and compared them to those in healthy controls. This evidence concerns the gene LGALS3 and type 2 diabetes mellitus.